Advances in biomarkers and stem cell-targeted therapy for hepatocellular carcinoma / 药学学报
Acta Pharmaceutica Sinica
; (12): 709-715, 2018.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-779926
Biblioteca responsável:
WPRO
ABSTRACT
Primary hepatocellular carcinoma as the main pathological type of liver cancer is one of the common malignant tumors in our country. Liver cancer stem cells (LCSCs) have the characteristics of multidrug resistance, anti-radiotherapy and high tumorigenicity in addition to the characteristics of stem cells, namely, self-renewal, multi-directional differentiation and unlimited proliferation. Based on the above features, relapse and metastasis often occur after the patients being treated with conventional methods, which results in poor prognosis. Effective treatment targeting LCSCs has the potential to cure hepatocellular carcinoma (HCC) completely. This article reviews the common biomarkers used in identification of LCSCs and development of stem cell-targeted therapy for HCC.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2018
Tipo de documento:
Artigo